Photo of Naval Daver from vjhemonc.com
Jun 19, 2024, 21:45
Fadi Haddad: Phase 1/2 trial of DSP-5336 menin inhibitor by Naval Daver
Fadi Haddad, Assistant Professor, Leukemia Department at MD Anderson Cancer Center, shared a post on X/Twitter:
“Phase 1/2 trial of DSP-5336 menin inhibitor by Naval Daver from MD Anderson Cancer Center:
- R/R AML with KMT2Ar or NPM1 mutation
- CR/CRh=17% in KMT2Ar and 33% in NPM1m
- DS=5.7%, no DLT Dose optimization ongoing for RP2D”
Source: Fadi Haddad/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 12:18
Dec 21, 2024, 11:52
Dec 21, 2024, 11:30
Dec 21, 2024, 11:25
Dec 21, 2024, 11:18